Welcome back to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this new season, we chat to Dr Simon Curtis about the upcoming Autumn 2025 Hot Topics course, then discuss three new pieces of research.First, in the Lancet, which are the best anti-hypertensives, what effect does increasing a dose actually have and how good are combinations? Second, in the NEJM, does giving all the drugs improve CKD outcomes? The case for finerenone and empagliflozin. Third, do ADHD drugs help outcomes beyond core symptoms such as accidents, suicide and crime? But can we rely on the research method used...?References<a href='https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00991-2/abstract'>Lancet Antihypertensive Efficacy Paper</a><a href='https://www.nejm.org/doi/full/10.1056/NEJMoa2410659'>NEJM Finerenone &amp; Empagliflozin</a><a href='https://www.ispor.org/docs/default-source/euro2023/projected-prevalence-of-acute-chronic-and-end-stage-kidney-disease-in-the-uk-from-2023-to-2033132375-pdf.pdf?sfvrsn=725fa82_0'>Report on trends in CKD</a><a href='https://www.bmj.com/content/390/bmj-2024-083658'>BMJ ADHD meds &amp; prevention of complications</a>www.nbmedical.com/podcast

<description>&lt;p&gt;Welcome back to the &lt;b&gt;Hot Topics podcast from NB Medical with Dr Neal Tucker&lt;/b&gt;. In this new season, we chat to Dr Simon Curtis about the upcoming Autumn 2025 Hot Topics course, then discuss three new pieces of research.&lt;/p&gt;&lt;p&gt;First, in the Lancet,&lt;b&gt; which are the best anti-hypertensives&lt;/b&gt;, what effect does increasing a dose actually have and how good are combinations? Second, in the NEJM, &lt;b&gt;does giving all the drugs improve CKD outcomes&lt;/b&gt;? The case for finerenone and empagliflozin. Third, &lt;b&gt;do ADHD drugs help outcomes&lt;/b&gt; beyond core symptoms such as accidents, suicide and crime? But can we rely on the research method used...?&lt;/p&gt;&lt;p&gt;References&lt;/p&gt;&lt;p&gt;&lt;a href='https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00991-2/abstract'&gt;Lancet Antihypertensive Efficacy Paper&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href='https://www.nejm.org/doi/full/10.1056/NEJMoa2410659'&gt;NEJM Finerenone &amp;amp; Empagliflozin&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href='https://www.ispor.org/docs/default-source/euro2023/projected-prevalence-of-acute-chronic-and-end-stage-kidney-disease-in-the-uk-from-2023-to-2033132375-pdf.pdf?sfvrsn=725fa82_0'&gt;Report on trends in CKD&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href='https://www.bmj.com/content/390/bmj-2024-083658'&gt;BMJ ADHD meds &amp;amp; prevention of complications&lt;/a&gt;&lt;/p&gt;&lt;p&gt;www.nbmedical.com/podcast&lt;/p&gt;</description>

Welcome back to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this new season, we chat to Dr Simon Curtis about the upcoming Autumn 2025 Hot Topics course, then discuss three new pieces of research. First, in the Lancet, which are the best anti-hypertensives, what effect does increasing a dose actually have and how good are combinations? Second, in the NEJM, does giving all the drugs improve CKD outcomes? The case for finerenone and empagliflozin. Third, do ADHD drugs help ou...

NB Hot Topics Podcast

S7 E1: Best BP Meds; Preventing End-Stage CKD; ADHD & Risky Behaviours

S7 E1: Best BP Meds; Preventing End-Stage CKD; ADHD & Risky Behaviours

Description